{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-036062","form_type":"8-K","ticker":null,"cik":"0001113148","company_name":"INFINITY PHARMACEUTICALS, INC.","filed_at":"2023-07-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.170058+00:00","generated_at":"2026-06-13T02:49:30.838548+00:00","sec_items":["2.05","5.02","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Infinity Pharma cuts 78% of workforce, three directors resign, seeks strategic alternative for eganelisib","bullets":["Headcount reduced by 21 positions (78% of workforce); expects $3.4M severance charge in Q3 2023.","Three board members (Agresta, Kango, Schwartz) resign; remaining five directors serve without compensation.","Company hires SSG Capital Advisors to lead strategic process to maximize value of eganelisib.","Company evaluating withdrawal of Nasdaq delisting appeal; withdrawal likely leads to stock delisting.","Merger agreement with MEI Pharma terminated; seeking alternative strategic transaction for eganelisib."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-036062","json":"https://secwatch.observer/filing/0001140361-23-036062.json","markdown":"https://secwatch.observer/filing/0001140361-23-036062.md","text":"https://secwatch.observer/filing/0001140361-23-036062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1113148/000114036123036062/0001140361-23-036062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1113148/000114036123036062/brhc20056430_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T02:49:30.838548+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4c2a36cc8a","claim":"Sujay R. Kango resigned as Director at INFINITY PHARMACEUTICALS, INC..","evidence_excerpt":"On July 24, 2023, each of Samuel Agresta, Sujay R. Kango and Brian Schwartz resigned from the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1113148/000114036123036062/0001140361-23-036062-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"7618c6aee4","claim":"Samuel Agresta resigned as Director at INFINITY PHARMACEUTICALS, INC..","evidence_excerpt":"On July 24, 2023, each of Samuel Agresta, Sujay R. Kango and Brian Schwartz resigned from the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1113148/000114036123036062/0001140361-23-036062-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"c42b87ed89","claim":"Brian Schwartz resigned as Director at INFINITY PHARMACEUTICALS, INC..","evidence_excerpt":"On July 24, 2023, each of Samuel Agresta, Sujay R. Kango and Brian Schwartz resigned from the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1113148/000114036123036062/0001140361-23-036062-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"cc39b6fe1ff0ea421cbe97d753c8909359b7160f","claim":"INFINITY PHARMACEUTICALS, INC. announced a restructuring with charges of approximately $3.4 million (21 positions, representing approximately 78% of the Company’s workforce).","evidence_excerpt":"reduction is expected to be completed by the end of the third quarter of 2023. The Company expects to incur a one-time charge in the third quarter of 2023 of approximately $3.4 million in severance and restructuring costs in connection with the workforce reduction. This charge primarily relates to severance payments and employee benefits. The estimates of","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1113148/000114036123036062/0001140361-23-036062-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $3.4 million"},{"label":"Headcount","value":"21 positions, representing approximately 78% of the Company’s workforce"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}